About this trial
This study aims to evaluate whether a single oral dose of nicotinamide riboside (NR), a precursor of nicotinamide adenine dinucleotide (NAD+), has acute effects on sleep in healthy adults who report mild sleep difficulties. NR is widely used as a nutritional supplement and is known to increase cellular NAD+ levels, which may influence physiological processes linked to sleep-wake regulation.
In this randomized, double-blind, placebo-controlled study, 20 healthy adults will complete two overnight sleep assessments using polysomnography (PSG), the gold-standard sleep monitoring method. After a baseline night of sleep recording, participants will receive either NR or a placebo before bedtime on the second night. Researchers will compare sleep duration and sleep structure before and after the intervention to determine whether NR has an acute effect on objective sleep quality.
The study will also evaluate safety and collect participants' subjective sleep impressions. Findings may help clarify whether NR, a widely used nutritional supplement, has measurable short-term effects on human sleep.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Healthy males or females aged 18 to 60 years inclusive;
Screening using the Pittsburgh Sleep Quality Index (PSQI) scale with a total score between 5 and 10, indicating mild subjective sleep disturbance;
Voluntarily participate in this study and sign a written informed consent form;
Able to understand the study procedures and willing to comply with all laboratory regulations.
Disqualifiers
History of any serious neurological, cardiovascular, respiratory, hepatic, renal, hematological, or psychiatric disorders;
Medically diagnosed sleep disorders (e.g., insomnia, sleep apnea syndrome, restless legs syndrome);
Regular use within the past month of any medication or supplement that may affect sleep (e.g., sedatives, antidepressants, antihistamines, melatonin);
Known allergy to nicotinamide riboside (NR) or any component of the study product;
Trial design
Parallel
Treatments tested in this trial
Nicotinamide Riboside (NR)
Dietary supplementA single oral dose of 600 mg NR, an NAD+ precursor compound, provided in capsule form. The dose and timing are standardized for all participants.
Placebo
Other interventionThe placebo capsule is visually identical to the NR capsule but contains inert excipients without active pharmacological components.
Treatment groups
Trial outcomes
Primary outcomes
Total Sleep Time (TST)
Total amount of sleep obtained during the overnight PSG recording, measured in minutes.
Secondary outcomes
Sleep Latency
Duration from lights-off to the first epoch of any sleep stage during PSG, measured in minutes.
Wake After Sleep Onset
Total duration of wakefulness after initial sleep onset but before final awakening, measured in minutes via PSG.
Sleep Stage Distribution
Minutes spent in N1, N2, N3, and REM sleep during overnight PSG, recorded as absolute minutes for each stage.
Leeds Sleep Evaluation Questionnaire
Self-reported subjective sleep quality assessed using the Leeds Sleep Evaluation Questionnaire (LSEQ). The outcome is reported as a total score ranging from 0 to 10, with higher scores indicating better perceived sleep quality and better condition upon awakening.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: